Comera Life Sciences (CMRA) Stock Price, News & Analysis

Company Overview

Comera Life Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics for neurodegenerative and neuropsychiatric disorders. Utilizing a proprietary platform designed to optimize blood–brain barrier penetration, Comera’s research seeks to address the underlying proteinopathies that characterize diseases such as Parkinson’s, Alzheimer’s, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The company’s lead program is directed at modulating alpha-synuclein aggregation, a key driver of Parkinson’s disease pathology. In parallel, Comera is advancing chemistry programs targeting tau and beta-amyloid in Alzheimer’s disease, as well as TDP-43 proteinopathies in ALS and FTD. Each candidate is engineered for central nervous system exposure, with the goal of slowing or halting disease progression by directly intervening in pathogenic protein aggregation pathways.

Headquartered in Cambridge, Massachusetts, Comera Life Sciences operates a research and development hub in the Boston biotech ecosystem. The company leverages collaborative partnerships and academic alliances to accelerate its preclinical-to-clinical transition. With an experienced scientific management team drawn from leading neuroscience and drug-development organizations, Comera is positioning its pipeline to enter first-in-human trials in the near term.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 9,214 shs
• Market Capitalization: $3 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CMRA
• CIK: 1907685
• Web: comeralifesciences.com
• Phone: 617-871-2101
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.00 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 30,740,000
• Free Float: 28,002,000
• Market Cap: $3 thousand
• Optionable: Not Optionable
• Beta: 1.05